Format
Sort by

Send to

Choose Destination

Search results

Items: 1 to 20 of 34

1.

Discovering potential serological biomarker for chronic Hepatitis B Virus-related hepatocellular carcinoma in Chinese population by MAL-associated serum glycoproteomics analysis.

Liu T, Liu D, Liu R, Jiang H, Yan G, Li W, Sun L, Zhang S, Liu Y, Guo K.

Sci Rep. 2017 Jan 12;7:38918. doi: 10.1038/srep38918.

2.

Galectin-3 and IL-33/ST2 axis roles and interplay in diet-induced steatohepatitis.

Pejnovic N, Jeftic I, Jovicic N, Arsenijevic N, Lukic ML.

World J Gastroenterol. 2016 Nov 28;22(44):9706-9717. Review.

3.

Oncogenic driver genes and the inflammatory microenvironment dictate liver tumor phenotype.

Matter MS, Marquardt JU, Andersen JB, Quintavalle C, Korokhov N, Stauffer JK, Kaji K, Decaens T, Quagliata L, Elloumi F, Hoang T, Molinolo A, Conner EA, Weber A, Heikenwalder M, Factor VM, Thorgeirsson SS.

Hepatology. 2016 Jun;63(6):1888-99. doi: 10.1002/hep.28487.

PMID:
26844528
4.

[Change in Serum Levels of New Hepatic Fibrosis Marker "Mac-2 Binding Protein Glycosylation isomer (M2BPGi)" in Patients with Chronic Hepatitis C during the Treatment of Pegylated Interferon and Ribavirin].

Ishida H, Suetsugu A, Nakamura M, Tauchi R, Nakayama J, Katano Y, Shirakami Y, Furuta N, Ito H, Seishima M.

Rinsho Byori. 2015 Aug;63(8):901-6. Japanese.

PMID:
26638424
5.

Galectin 3 regulates HCC cell invasion by RhoA and MLCK activation.

Serizawa N, Tian J, Fukada H, Baghy K, Scott F, Chen X, Kiss Z, Olson K, Hsu D, Liu FT, Török NJ, Zhao B, Jiang JX.

Lab Invest. 2015 Oct;95(10):1145-56. doi: 10.1038/labinvest.2015.77.

6.

Galectin-3 Ablation Enhances Liver Steatosis, but Attenuates Inflammation and IL-33-Dependent Fibrosis in Obesogenic Mouse Model of Nonalcoholic Steatohepatitis.

Jeftic I, Jovicic N, Pantic J, Arsenijevic N, Lukic ML, Pejnovic N.

Mol Med. 2015 May 22;21:453-65. doi: 10.2119/molmed.2014.00178.

7.

Prognostic significance of serum galectin-3 levels in patients with hepatocellular cancer and chronic viral hepatitis.

Ulu M, Alacacioglu A, Yuksel E, Pamukk BO, Bozkaya G, Ari A, Yuksel A, Sop G, Alacacioglu I.

Saudi J Gastroenterol. 2015 Jan-Feb;21(1):47-50. doi: 10.4103/1319-3767.151228.

8.

CXCR7 stimulates MAPK signaling to regulate hepatocellular carcinoma progression.

Lin L, Han MM, Wang F, Xu LL, Yu HX, Yang PY.

Cell Death Dis. 2014 Oct 23;5:e1488. doi: 10.1038/cddis.2014.392.

9.

Galectin-3 is associated with a poor prognosis in primary hepatocellular carcinoma.

Jiang SS, Weng DS, Wang QJ, Pan K, Zhang YJ, Li YQ, Li JJ, Zhao JJ, He J, Lv L, Pan QZ, Xia JC.

J Transl Med. 2014 Sep 27;12:273. doi: 10.1186/s12967-014-0273-3.

10.

A new human 3D-liver model unravels the role of galectins in liver infection by the parasite Entamoeba histolytica.

Petropolis DB, Faust DM, Deep Jhingan G, Guillen N.

PLoS Pathog. 2014 Sep 11;10(9):e1004381. doi: 10.1371/journal.ppat.1004381.

11.

Insights into EPR effect versus lectin-mediated targeted delivery: biodegradable polycarbonate micellar nanoparticles with and without galactose surface decoration.

Ebrahim Attia AB, Oh P, Yang C, Tan JP, Rao N, Hedrick JL, Yang YY, Ge R.

Small. 2014 Nov 12;10(21):4281-6. doi: 10.1002/smll.201401295.

PMID:
25091699
12.

Galectin-3 regulates hepatic progenitor cell expansion during liver injury.

Hsieh WC, Mackinnon AC, Lu WY, Jung J, Boulter L, Henderson NC, Simpson KJ, Schotanus B, Wojtacha D, Bird TG, Medine CN, Hay DC, Sethi T, Iredale JP, Forbes SJ.

Gut. 2015 Feb;64(2):312-21. doi: 10.1136/gutjnl-2013-306290.

PMID:
24837171
13.

Downregulation of galectin-3 causes a decrease in uPAR levels and inhibits the proliferation, migration and invasion of hepatocellular carcinoma cells.

Zheng D, Hu Z, He F, Gao C, Xu L, Zou H, Wu Z, Jiang X, Wang J.

Oncol Rep. 2014 Jul;32(1):411-8. doi: 10.3892/or.2014.3170.

PMID:
24807674
14.

Galectin-3 and matrix metalloproteinase-9: Perspective in management of hepatocellular carcinoma.

Eisa NH, Ebrahim MA, Ragab M, Eissa LA, El-Gayar AM.

J Oncol Pharm Pract. 2015 Oct;21(5):323-30. doi: 10.1177/1078155214532698.

PMID:
24769518
15.

Hierarchical and selective roles of galectins in hepatocarcinogenesis, liver fibrosis and inflammation of hepatocellular carcinoma.

Bacigalupo ML, Manzi M, Rabinovich GA, Troncoso MF.

World J Gastroenterol. 2013 Dec 21;19(47):8831-49. doi: 10.3748/wjg.v19.i47.8831. Review.

16.

Annexin A7 and its binding protein galectin-3 influence mouse hepatocellular carcinoma cell line in vitro.

Song L, Mao J, Zhang J, Ibrahim MM, Li LH, Tang JW.

Biomed Pharmacother. 2014 Apr;68(3):377-84. doi: 10.1016/j.biopha.2013.10.011.

PMID:
24373698
17.

Therapy of experimental NASH and fibrosis with galectin inhibitors.

Traber PG, Zomer E.

PLoS One. 2013 Dec 18;8(12):e83481. doi: 10.1371/journal.pone.0083481.

18.

Identification of candidate biomarkers for hepatocellular carcinoma in plasma of HCV-infected cirrhotic patients by 2-D DIGE.

Ferrín G, Ranchal I, Llamoza C, Rodríguez-Perálvarez ML, Romero-Ruiz A, Aguilar-Melero P, López-Cillero P, Briceño J, Muntané J, Montero-Álvarez JL, De la Mata M.

Liver Int. 2014 Mar;34(3):438-46. doi: 10.1111/liv.12277.

PMID:
23944848
20.

Deficiency in galectin-3 promotes hepatic injury in CDAA diet-induced nonalcoholic fatty liver disease.

Nomoto K, Nishida T, Nakanishi Y, Fujimoto M, Takasaki I, Tabuchi Y, Tsuneyama K.

ScientificWorldJournal. 2012;2012:959824. doi: 10.1100/2012/959824.

Items per page

Supplemental Content

Loading ...
Support Center